Rekover Therapeutics is a clinical-stage biotechnology company developing nalfurafine as a first-in-class remyelinating therapy for multiple sclerosis
Rekover Therapeutics is a clinical-stage biotechnology company developing nalfurafine as a first-in-class remyelinating therapy for multiple sclerosis. The company aims to fill the gap in existing therapies that only slow MS progression, by promoting recovery from disability.